clinical trial · NCT06223958
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
Neovascular Age-Related Macular DegenerationOTX-TKI (axitinib implant)Aflibercept
brief summary
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
started
Jan 29, 2024
primary completion
Apr 29, 2026
completion
Sep 27, 2027
last updated
Apr 18, 2025
official title
A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol